Biocon, a company in the Pharmaceuticals industry, reported revenue of ₹4,389 crore and net profit of ₹57 crore for the September 2026 quarter.
Biocon (NSE: BIOCON) closed at ₹364.40 on 20 Nov 2026, down 7.8% over the past year. Its market capitalisation is ₹59,386 crore and it trades at 87.2 times earnings.
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.